| Full Name |
SARS-Associated Coronavirus M
|
Abbreviated Name-1 |
SARS-Cov M; |
| Documents |
|---|
| Figures |
|---|
| Reference |
|---|
Tripp RA, et al. Monoclonal antibodies to SARS-associated coronavirus (SARS-CoV): identification of neutralizing and antibodies reactive to S, N, M and E viral proteins. J. Virol Methods. Sep 2005; 128(1-2): 21-28.
He ML, et al. Kinetics and synergistic effects of siRNAs targeting structural and replicase genes of SARS-associated coronavirus. FEBS. Lett. May 2006; 580(10): 2414-2420.
|
|
Description |
The genome of SARS-CoV is 29,727 nucleotides in length, and the genome organization is similar to that of other coronaviruses. Open-reading frames corresponding to the predicted polymerase protein (polymerase 1a, 1b), spike protein (S), small membrane protein (E), membrane protein (M), and nucleocapsid protein (N), plus several other open-reading frames of unknown function. SARS-Associated Coronavirus M is a E. coli derived recombinant protein. The protein contains the M protein immunodominant regions. |
Purity |
Protein is >95% pure as determined by 10% PAGE (coomassie staining). |
Storage |
Protein is shipped at ambient temperature. Upon arrival, store at -20°C. |
Concentration |
1 mg/ml in 50 mM Tris-HCl, 60 mM NaCl, 50% glycerol. |
Stability |
Five year frozen, 6 month at +4°C. |
Specificity |
Immunoreactive with sera of SARS-infected individuals. |
Applications |
Antigen in ELISA and Western blots, excellent antigen for detection of SARS with minimal specificity problems. |
Note |
; |
